Oddbjørn Straume, MD, PhD, associate professor, department of Clinical Science, Haukeland University Hospital, discusses a study investigating BGB324 with pembrolizumab or dabrafenib/trametinib in patients with advanced non-resectable or metastatic melanoma. 

Related Content

Treating Melanoma After Immunotherapy and Targeted Therapies

April 17, 2017 10:38pm

By Richard Carvajal, MD

Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma

April 06, 2017 07:06pm

By Yousef Zakharia, MD

How PD-1 and PD-L1 Act in Various Cancers

July 16, 2013 10:54pm

By Antoni Ribas, MD, PhD